Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys ABT Stock

Democratic Representative Gilbert Ray Cisneros Jr. picked up shares of Abbott Laboratories [ABT] in a trade valued between $1,001 and $15,000 on June 16, 2026. The transaction was revealed in a periodic transaction report filed under the STOCK Act and disclosed to the public on July 2, 2026.

ABT Abbott Laboratories

$104.06 ▼ -14.13% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Gilbert Ray Cisneros Jr.'s Abbott Trade

According to the congressional filing, the purchase was executed by the House Democrat representing California's 31st district. The trade follows several other recent disclosures by the lawmaker, continuing a pattern of equity investments tracked through mid-September and late September filings.

Other Institutional Activity in Abbott Laboratories

Other large financial players adjusted their positions in the medical device maker around the same reporting window. Capital International Investors trimmed its holdings by 2,842,222 shares, leaving it with 34,654,113 shares valued at about $3,634,869,891 as of June 30, 2026. Meanwhile, Y-Intercept added 250,717 shares to end with 250,717 shares worth roughly $24,778,361 by October 16, 2026. Elser Financial Planning grew its holdings by 2,209 shares, ending with 2,209 shares worth about $218,315. Global Strategic Investment Solutions also established a stake, adding 2,291 shares to hold 2,291 shares valued at roughly $226,402.

Abbott Laboratories Stock Up 1.9%

Abbott Laboratories shares recently traded around $104.33 as of October 16, 2026. On the day of the trade, June 16, 2026, the stock closed at $89.43.

Recent Earnings

Abbott generated $46,585,000,000 in trailing-twelve-month revenue with trailing earnings of $3.10 per share. The company reported a net profit margin of 11.6% alongside a return on equity of 10.6% and year-over-year revenue growth of 13.0%. The company's next earnings update is slated for October 21, 2026.

Dividend

Abbott pays an annual dividend with a current yield of 2.41% and a payout ratio of 78.7%.

Insider Buying and Selling at Abbott Laboratories

Company insiders were active in the months surrounding the trade, with executives such as Chief Financial Officer Philip P. Boudreau and directors Daniel J. Starks and John G. Stratton buying shares between April and May 2026. Later, in August 2026, officer Louis H. Morrone sold 5,850 shares at an average price of $109.83 for a total value of $642,506.

Analysts Set New Price Targets

Wall Street firms updated their outlooks on the stock following its summer earnings reports. Wolfe Research upgraded the stock to an outperform rating with a $130 price target in August, while Citigroup and TD Cowen reiterated buy ratings with price targets reaching up to $135. The stock carries a consensus recommendation key of strong_buy from 26 analysts with a mean price target of $120.72.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois. The firm creates, makes, and sells medical devices, diagnostic equipment, nutritional products, and established pharmaceutical therapies worldwide.

Bottom Line

Congressional stock disclosures are reported after the fact and do not necessarily signal immediate investment moves. Investors watching Abbott will look toward its upcoming earnings report on October 21, 2026, for further insight into its financial health.